RATIONALE FOR INCLUSION IN PA PROGRAM

Background
Dupixent is a medication used for the treatment of atopic dermatitis (eczema). Atopic dermatitis, a chronic inflammatory skin disease, is often referred to as “eczema,” which is a general term for several types of inflammation of the skin. In atopic dermatitis, the skin develops red, scaly and crusted bumps, which are extremely itchy. Scratching leads to swelling, cracking, “weeping” clear fluid, and finally, coarsening and thickening of the skin. Dupixent is an antibody that binds to a protein that causes inflammation. By binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis (1).

Regulatory Status
FDA-approved indications: Dupixent is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

Summary
Dupixent is a medication used for treatment of atopic dermatitis (eczema). Dupixent is an antibody that binds to a protein that causes inflammation. By binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis. The safety and effectiveness of Dupixent in pediatric patients (<18 years of age) have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Dupixent while maintaining optimal therapeutic outcomes.

References

